{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014330","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.259811+00:00","generated_at":"2026-06-04T00:11:44.096206+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mangoceuticals closes $500K initial tranche of Series B Preferred Stock and 3.3M warrants","bullets":["Initial closing: $500,000 for 500 Series B shares (stated value $1,100 each, 10% discount) plus warrants for 3.3M shares at $0.26.","Second closing of $250,000 and third closing of $750,000 subject to stockholder approval and SEC effectiveness.","Series B Preferred: 10% cumulative dividend, convertible at lower of $0.40 or 90% of three lowest VWAPs in prior 10 days, floor $0.035.","Warrants exercisable from Oct 4, 2024 for 5 years; cashless if no effective registration after 120 days.","Company must hold stockholder meeting within 30 days to waive 19.99% exchange cap and increase authorized shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014330","json":"https://secwatch.observer/filing/0001493152-24-014330.json","markdown":"https://secwatch.observer/filing/0001493152-24-014330.md","text":"https://secwatch.observer/filing/0001493152-24-014330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224014330/0001493152-24-014330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224014330/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:11:44.096206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba1daa2bc00ebe9af3fb8c3ad85a165f4a5a9712","claim":"MANGOCEUTICALS, INC. entered into Securities Purchase Agreement with an institutional accredited investor valued at $1,650,000 (effective 2024-04-05).","evidence_excerpt":"Effective on April 5, 2024 (the \" Initial Closing Date \"), Mangoceuticals, Inc., a Texas corporation (the \" Company \", \" we \" and \" us \"), agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024 (the \" SPA \"), with an institutional accredited investor (the \" Purchaser \"), pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 1,500 shares of Series B Convertible Preferred Stock (\" Series B Preferred Stock \") of the Company for $1,650,000, and warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224014330/0001493152-24-014330-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional accredited investor"},{"label":"Value","value":"$1,650,000"},{"label":"Effective","value":"2024-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}